US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
MXPA03000289A
(es)
*
|
2000-08-04 |
2003-06-06 |
Warner Lambert Co |
Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenil-pirido (2,3-d) pirimidin-7-onas..
|
DK1417207T3
(da)
*
|
2000-08-04 |
2005-12-27 |
Warner Lambert Co |
Fremgangsmåde til fremstilling af 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-oner
|
WO2002064594A2
(en)
*
|
2001-02-12 |
2002-08-22 |
F. Hoffmann-La Roche Ag |
6-substituted pyrido-pyrimidines
|
JP4166991B2
(ja)
|
2001-02-26 |
2008-10-15 |
田辺三菱製薬株式会社 |
ピリドピリミジンまたはナフチリジン誘導体
|
EP1408985A4
(en)
*
|
2001-06-21 |
2006-03-22 |
Ariad Pharma Inc |
NEW PYRIDOPYRIMIDONE AND ITS USES
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
EP1470124B1
(en)
|
2002-01-22 |
2005-12-28 |
Warner-Lambert Company LLC |
2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES
|
CA2492112A1
(en)
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
US7129351B2
(en)
|
2002-11-04 |
2006-10-31 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
JP4666256B2
(ja)
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
含窒素複素環化合物およびその医薬用途
|
BRPI0409366A
(pt)
|
2003-04-10 |
2006-04-25 |
Hoffmann La Roche |
compostos de pirimido
|
ATE412650T1
(de)
*
|
2003-07-11 |
2008-11-15 |
Warner Lambert Co |
Isethionat salz eines selektiven cdk4 inhibitors
|
AU2004261459B2
(en)
|
2003-07-22 |
2008-06-26 |
Astex Therapeutics Limited |
3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
|
MXPA06001202A
(es)
|
2003-07-29 |
2006-08-31 |
Xenon Pharmaceuticals Inc |
Derivados piridilo y su uso como agentes terapeuticos.
|
DE602004005238T2
(de)
*
|
2003-11-13 |
2007-11-08 |
F. Hoffmann-La Roche Ag |
Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7-one
|
WO2005058341A2
(en)
*
|
2003-12-11 |
2005-06-30 |
Theravance, Inc. |
Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
JP4989233B2
(ja)
*
|
2004-02-14 |
2012-08-01 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤としての化合物および組成物
|
WO2005082903A1
(en)
*
|
2004-02-18 |
2005-09-09 |
Warner-Lambert Company Llc |
2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
DE602005004286T2
(de)
*
|
2004-06-11 |
2009-01-02 |
Japan Tobacco Inc. |
5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
JP2008519840A
(ja)
|
2004-11-10 |
2008-06-12 |
ジェンザイム・コーポレイション |
糖尿病の処置方法
|
US20060142312A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
AU2006207321B2
(en)
*
|
2005-01-21 |
2012-09-06 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
JP2008528469A
(ja)
*
|
2005-01-21 |
2008-07-31 |
アステックス・セラピューティクス・リミテッド |
ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
US20090036435A1
(en)
*
|
2005-01-21 |
2009-02-05 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
EP1852432A4
(en)
*
|
2005-02-25 |
2010-04-14 |
Ono Pharmaceutical Co |
NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE
|
PE20100741A1
(es)
*
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
|
UY29440A1
(es)
*
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
MY153424A
(en)
|
2005-05-10 |
2015-02-13 |
Incyte Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
KR100734837B1
(ko)
*
|
2005-09-16 |
2007-07-03 |
한국전자통신연구원 |
다중 생체 인식 시스템 및 그 방법
|
EP1931667A1
(en)
*
|
2005-09-28 |
2008-06-18 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
JP5480503B2
(ja)
*
|
2005-10-07 |
2014-04-23 |
エクセリクシス, インク. |
PI3Kαのピリドピリミジノン型阻害剤
|
PL1940839T3
(pl)
*
|
2005-10-07 |
2013-12-31 |
Exelixis Inc |
Pirydopirymidynonowe inhibitory PI3Kalfa
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
HUE026057T2
(en)
|
2006-05-09 |
2016-05-30 |
Genzyme Corp |
Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
|
WO2008032157A2
(en)
*
|
2006-09-08 |
2008-03-20 |
Pfizer Products Inc. |
Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
AP2710A
(en)
|
2006-09-15 |
2013-07-30 |
Pfizer Prod Inc |
Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
|
JP2010506902A
(ja)
*
|
2006-10-16 |
2010-03-04 |
ジーピーシー・バイオテック・インコーポレーテッド |
ピリド[2,3−d]ピリミジン類およびキナーゼ阻害剤としてのそれらの使用
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
CA2668731A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Tobias Gabriel |
Kinase inhibitors and methods for using the same
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
KR101640263B1
(ko)
|
2007-10-05 |
2016-07-15 |
젠자임 코포레이션 |
세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
|
EA201001030A1
(ru)
|
2007-12-19 |
2011-02-28 |
Амген Инк. |
Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
|
JP5530422B2
(ja)
|
2008-04-07 |
2014-06-25 |
アムジエン・インコーポレーテツド |
細胞周期阻害薬としてのgem−二置換およびスピロ環式アミノピリジン/ピリミジン
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
KR102031538B1
(ko)
|
2008-07-08 |
2019-11-08 |
인사이트 홀딩스 코포레이션 |
인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸
|
US8389517B2
(en)
|
2008-07-28 |
2013-03-05 |
Genzyme Corporation |
Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
|
WO2010020675A1
(en)
*
|
2008-08-22 |
2010-02-25 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
US20110224221A1
(en)
*
|
2008-10-01 |
2011-09-15 |
Sharpless Norman E |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
JP2012504646A
(ja)
*
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
選択的サイクリン依存性キナーゼ4/6阻害剤を用いた化学療法化合物に対する造血系の防護
|
CA2738768C
(en)
|
2008-10-03 |
2017-10-31 |
Genzyme Corporation |
2-acylaminopropoanol-type glucosylceramide synthase inhibitors
|
JO2885B1
(en)
*
|
2008-12-22 |
2015-03-15 |
ايلي ليلي اند كومباني |
Protein kinase inhibitors
|
PL2414356T3
(pl)
|
2009-04-03 |
2016-02-29 |
Hoffmann La Roche |
Kompozycje {3-[5-(4-chlorofenylo)-1H-pirolo[2,3-b]pirydyno-3-karbonylo]-2,4-difluorofenylo}-amidu kwasu propano-1-sulfonowego i ich zastosowania
|
JP2012526850A
(ja)
*
|
2009-05-13 |
2012-11-01 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
サイクリン依存性キナーゼ阻害剤及びその用法
|
EP2474540A4
(en)
*
|
2009-08-31 |
2013-03-13 |
Nippon Chemiphar Co |
GPR119 AGONIST
|
KR20120104200A
(ko)
*
|
2009-10-09 |
2012-09-20 |
아프락시스 인코포레이티드 |
Cns 장애의 치료를 위한 8에틸6(아릴)피리도[2,3d]피리미딘7(8h)온
|
NZ629615A
(en)
|
2009-11-06 |
2016-01-29 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
CA2784749C
(en)
*
|
2009-12-18 |
2017-12-12 |
E. Premkumar Reddy |
Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
|
PH12012501361A1
(en)
|
2009-12-31 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Tricyclic compounds for use as kinase inhibitors
|
ES2689177T3
(es)
*
|
2010-04-13 |
2018-11-08 |
Novartis Ag |
Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
|
TWI619713B
(zh)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
用於激酶調節的化合物和方法及其適應症
|
WO2011156786A2
(en)
*
|
2010-06-10 |
2011-12-15 |
Afraxis, Inc. |
6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
|
EP2580320B1
(en)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
DK2600719T3
(da)
|
2010-08-05 |
2014-12-15 |
Univ Temple |
2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
EP3381920B1
(en)
|
2010-10-25 |
2019-03-27 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
AU2011329763A1
(en)
|
2010-11-17 |
2013-05-09 |
Brigham And Women's Hospital |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
ES2696023T3
(es)
|
2011-02-07 |
2019-01-11 |
Plexxikon Inc |
Compuestos y métodos para la modulación de quinasas e indicaciones para ello
|
MX2013010871A
(es)
*
|
2011-03-23 |
2014-01-31 |
Amgen Inc |
Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
|
AU2012262489A1
(en)
|
2011-05-27 |
2013-04-04 |
Icahn School Of Medicine At Mount Sinai |
Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
|
CA2865167C
(en)
*
|
2012-03-14 |
2019-08-06 |
Lupin Limited |
Heterocyclyl compounds
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
ES2832497T3
(es)
|
2012-06-13 |
2021-06-10 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
US8802697B2
(en)
|
2012-07-11 |
2014-08-12 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
HK1213044A1
(zh)
|
2012-08-03 |
2016-06-24 |
Foundation Medicine, Inc. |
人乳头瘤病毒作为肿瘤预後的预测因子
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
CA2880083A1
(en)
|
2012-08-17 |
2014-02-20 |
Concert Pharmaceuticals, Inc. |
Deuterated baricitinib
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
AU2014220354B2
(en)
*
|
2013-02-21 |
2018-02-01 |
Pfizer Inc. |
Solid forms of a selective CDK4/6 inhibitor
|
CA3152117A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
JP2016512831A
(ja)
*
|
2013-03-15 |
2016-05-09 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたパルボシクリブ
|
SI2968290T1
(sl)
|
2013-03-15 |
2020-02-28 |
G1 Therapeutics, Inc., |
Prehodna zaščita normalnih celic med kemoterapijo
|
JP6449244B2
(ja)
|
2013-04-19 |
2019-01-09 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Fgfr抑制剤としての二環式複素環
|
CN104470921B
(zh)
*
|
2013-05-17 |
2017-05-03 |
上海恒瑞医药有限公司 |
吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
PT3395814T
(pt)
|
2013-10-25 |
2022-07-27 |
Blueprint Medicines Corp |
Inibidores do recetor do fator de crescimento de fibroblastos
|
AU2014368927B2
(en)
*
|
2013-12-20 |
2018-10-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of CDK and ERK inhibitors
|
AU2014375500B2
(en)
|
2013-12-31 |
2017-03-16 |
Xuanzhu Biopharmaceutical Co., Ltd. |
Kinase inhibitor and use thereof
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
WO2015161287A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of normal cells during chemotherapy
|
EP3148532B1
(en)
|
2014-05-28 |
2021-03-03 |
Piramal Enterprises Limited |
Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
|
JP6490215B2
(ja)
|
2014-07-24 |
2019-03-27 |
ベータ ファーマ,インコーポレイテッド |
サイクリン依存性キナーゼ(cdk)阻害剤としての2−h−インダゾール誘導体およびその治療上の使用
|
CA2954189A1
(en)
*
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
US20170217962A1
(en)
*
|
2014-07-31 |
2017-08-03 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
AR101504A1
(es)
*
|
2014-08-11 |
2016-12-21 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
|
EP3180007A1
(en)
*
|
2014-08-14 |
2017-06-21 |
Sun Pharmaceutical Industries Ltd |
Crystalline forms of palbociclib
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
CN105111201B
(zh)
*
|
2014-10-16 |
2017-01-11 |
上海页岩科技有限公司 |
5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
CN105622638B
(zh)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
|
CN105616418A
(zh)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
含有细胞周期蛋白抑制剂的药物制剂及其制备方法
|
PL3218005T3
(pl)
|
2014-11-12 |
2023-05-02 |
Seagen Inc. |
Związki oddziałujące z glikanami i sposoby ich zastosowania
|
CN104496983B
(zh)
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
一种帕博西尼的制备方法
|
CN104447743B
(zh)
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
帕博西尼的制备方法
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
WO2016107605A1
(zh)
|
2014-12-31 |
2016-07-07 |
昆明积大制药股份有限公司 |
药物组合物及其制备方法
|
CN105732615B
(zh)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk激酶抑制剂
|
CN104610254B
(zh)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
一种帕博赛布的低成本制备方法
|
CZ201589A3
(cs)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Pevné formy soli Palbociclibu
|
TWI690533B
(zh)
|
2015-02-12 |
2020-04-11 |
南北兄弟藥業投資有限公司 |
Cdk類小分子抑制劑的化合物及其用途
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
EP3617205B1
(en)
|
2015-02-20 |
2021-08-04 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
AR104068A1
(es)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
CN106795159B
(zh)
*
|
2015-04-22 |
2018-12-28 |
江苏恒瑞医药股份有限公司 |
一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
|
TWI696617B
(zh)
*
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
RU2695337C2
(ru)
|
2015-05-29 |
2019-07-23 |
Тейдзин Фарма Лимитед |
ПРОИЗВОДНОЕ ПИРИДО[3,4-d]ПИРИМИДИНА И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМАЯ СОЛЬ
|
HRP20192065T1
(hr)
|
2015-06-04 |
2020-02-21 |
Pfizer Inc. |
Čvrsti oblici doziranja palbocikliba
|
CN104892604B
(zh)
*
|
2015-06-19 |
2016-08-24 |
北京康立生医药技术开发有限公司 |
一种cdk4抑制剂的合成方法
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
US10526326B2
(en)
|
2015-08-05 |
2020-01-07 |
Ratiopharm Gmbh |
Crystalline form and acetic acid adducts of palbociclib
|
CN105085517B
(zh)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
一种结晶型帕博西尼游离碱水合物及其制备方法
|
CN105130986B
(zh)
*
|
2015-09-30 |
2017-07-18 |
广州科擎新药开发有限公司 |
嘧啶或吡啶并吡啶酮类化合物及其应用
|
HU230962B1
(hu)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Palbociclib sók
|
CN106632311B
(zh)
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
一种帕博西尼晶型a和晶型b的制备方法
|
CN116217729A
(zh)
|
2015-11-12 |
2023-06-06 |
思进公司 |
聚糖相互作用化合物及使用方法
|
CN105418603A
(zh)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
一种高纯度帕布昔利布及其反应中间体的制备方法
|
CN106810536A
(zh)
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
一种蛋白激酶抑制剂及其制备方法和医药用途
|
US11225492B2
(en)
|
2015-12-13 |
2022-01-18 |
Hangzhou Innogate Pharma Co., Ltd. |
Heterocycles useful as anti-cancer agents
|
CN105418609B
(zh)
*
|
2015-12-31 |
2017-06-23 |
山东大学 |
4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
|
ES2994614T3
(en)
|
2015-12-31 |
2025-01-27 |
Shanghai Pharmaceuticals Holding Co Ltd |
Nitrogen-containing fused heterocyclic compound, as well as preparation method, intermediate, composition and application thereof
|
CN106967061A
(zh)
*
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
帕博西林的盐、晶型及其制备方法
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
WO2017161253A1
(en)
|
2016-03-18 |
2017-09-21 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
CN107266421B
(zh)
*
|
2016-04-08 |
2020-12-04 |
正大天晴药业集团股份有限公司 |
取代的苯并咪唑类衍生物
|
CN107286180B
(zh)
*
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
|
AU2017254708B2
(en)
*
|
2016-04-22 |
2021-09-16 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
|
CN106336411B
(zh)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
|
CN105949189B
(zh)
*
|
2016-06-05 |
2017-09-22 |
童明琼 |
一种用于治疗乳腺癌的帕博西尼的制备方法
|
AU2017290748A1
(en)
|
2016-07-01 |
2019-01-17 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
US10807978B2
(en)
|
2016-07-04 |
2020-10-20 |
Dr. Reddy's Laboratories Limited |
Process for preparation of palbociclib
|
US10597393B2
(en)
|
2016-07-07 |
2020-03-24 |
Plantex Ltd. |
Solid state forms of Palbociclib dimesylate
|
AU2017311645B2
(en)
*
|
2016-08-15 |
2021-05-27 |
Pfizer Inc. |
Pyridopyrimdinone CDK2/4/6 inhibitors
|
CN109803684B
(zh)
|
2016-08-23 |
2022-08-23 |
卫材 R&D 管理有限公司 |
用于治疗肝细胞癌的组合疗法
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
US10710999B2
(en)
|
2016-10-07 |
2020-07-14 |
Mylan Laboratories Limited |
Polymorph of an intermediate for palbociclib synthesis
|
MX2019004602A
(es)
|
2016-10-20 |
2019-06-17 |
Pfizer |
Agentes anti-proliferativos para tratar pah.
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
CN106565707B
(zh)
*
|
2016-11-03 |
2019-01-04 |
杭州科巢生物科技有限公司 |
帕博西尼新合成方法
|
US11865176B2
(en)
|
2016-11-08 |
2024-01-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
US20190275049A1
(en)
|
2016-11-16 |
2019-09-12 |
Pfizer Inc. |
Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
SI3546458T1
(sl)
|
2016-11-28 |
2021-03-31 |
Teijin Pharma Limited |
Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka
|
DK3546456T3
(da)
|
2016-11-28 |
2022-03-07 |
Teijin Pharma Ltd |
Krystal af pyrido[3, 4-d]pyrimidinderivat eller solvat deraf
|
CN110382495B
(zh)
|
2016-12-16 |
2022-04-05 |
基石药业(苏州)有限公司 |
Cdk4/6抑制剂
|
AR110728A1
(es)
|
2017-01-06 |
2019-04-24 |
G1 Therapeutics Inc |
Terapia combinada para el tratamiento del cáncer
|
CN108191857B
(zh)
*
|
2017-01-24 |
2020-10-23 |
晟科药业(江苏)有限公司 |
6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
|
US10729692B2
(en)
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
EP3589634A4
(en)
*
|
2017-03-03 |
2020-08-12 |
Auckland Uniservices Limited |
KINASE FGFR INHIBITORS AND PHARMACEUTICAL USES
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
IL269357B2
(en)
|
2017-03-16 |
2024-10-01 |
Eisai R&D Man Co Ltd |
A combination of ER? inhibitor and CDK 4/6 inhibitor for use in a method of treating breast cancer
|
CN108658855A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种含氮双环化合物及其制备方法和用途
|
CN108658854A
(zh)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
一种生物碱化合物及其制备方法和作为海洋防污剂的应用
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
KR20200016969A
(ko)
|
2017-06-16 |
2020-02-17 |
베타 파마, 인크. |
N-(2-(2-(디메틸아미노)에톡시)-4-메톡시-5-((4-(1-메틸-1h-인돌-3-일)피리미딘-2-일)아미노)페닐)아크릴아미드 및 그의 염의 제약 제제
|
AU2018291026B2
(en)
|
2017-06-29 |
2022-09-01 |
Pharmacosmos Holding A/S |
Morphic forms of GIT38 and methods of manufacture thereof
|
EA036060B1
(ru)
*
|
2017-07-17 |
2020-09-21 |
Пфайзер Инк. |
Пиридопиримидиноновые ингибиторы cdk2/4/6
|
US11529353B2
(en)
|
2017-07-28 |
2022-12-20 |
Synthon B.V. |
Pharmaceutical composition comprising Palbociclib
|
CN109384767B
(zh)
*
|
2017-08-08 |
2020-05-05 |
江苏恒瑞医药股份有限公司 |
一种吡啶并嘧啶类衍生物的制备方法及其中间体
|
WO2019043504A1
(en)
|
2017-08-31 |
2019-03-07 |
Novartis Ag |
METHODS OF SELECTING TREATMENT FOR PATIENTS WITH CANCER
|
CN107488175A
(zh)
*
|
2017-09-04 |
2017-12-19 |
上海微巨实业有限公司 |
一种帕博西林关键中间体的制备方法
|
EP3695408A4
(en)
|
2017-10-02 |
2021-12-15 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
RU2020124138A
(ru)
|
2017-12-22 |
2022-01-24 |
Хиберселл, Инк. |
Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
|
CN108586452A
(zh)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
一种帕博西尼中间体的合成方法
|
CN111989099A
(zh)
|
2018-01-29 |
2020-11-24 |
贝塔制药有限公司 |
作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途
|
CN108218861B
(zh)
*
|
2018-02-05 |
2019-07-23 |
黑龙江中医药大学 |
一种预防和治疗糖尿病的药物及其制备方法
|
KR102765922B1
(ko)
|
2018-02-06 |
2025-02-11 |
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 |
선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
|
MA52422A
(fr)
|
2018-02-27 |
2021-01-06 |
Incyte Corp |
Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
|
JP2021514975A
(ja)
|
2018-02-27 |
2021-06-17 |
ファイザー・インク |
サイクリン依存性キナーゼ阻害剤およびbet−ブロモドメイン阻害剤の組合せ
|
US11174257B2
(en)
|
2018-05-04 |
2021-11-16 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
JP2021523121A
(ja)
|
2018-05-04 |
2021-09-02 |
インサイト・コーポレイションIncyte Corporation |
Fgfr阻害剤の固体形態及びその調製プロセス
|
PL3793609T3
(pl)
|
2018-05-14 |
2024-05-13 |
Pfizer Inc. |
Preparat w postaci doustnego roztworu
|
WO2019222677A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
PL3802529T3
(pl)
|
2018-05-24 |
2024-03-25 |
Synthon B.V. |
Sposób wytwarzania palbocyklibu
|
MA53097A
(fr)
|
2018-07-05 |
2021-05-12 |
Incyte Corp |
Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
|
CN112533596A
(zh)
|
2018-07-23 |
2021-03-19 |
豪夫迈·罗氏有限公司 |
用pi3k抑制剂gdc-0077治疗癌症的方法
|
EP3840756A4
(en)
|
2018-08-24 |
2022-04-27 |
G1 Therapeutics, Inc. |
IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
|
JP6952747B2
(ja)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ
|
WO2020076432A1
(en)
|
2018-10-08 |
2020-04-16 |
Genentech, Inc. |
Methods of treating cancer with pi3k alpha inhibitors and metformin
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
WO2020114519A1
(zh)
*
|
2018-12-07 |
2020-06-11 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
EP3903828A4
(en)
|
2018-12-21 |
2022-10-05 |
Daiichi Sankyo Company, Limited |
ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
|
AU2019413360B2
(en)
|
2018-12-28 |
2025-05-22 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
WO2020140055A1
(en)
*
|
2018-12-28 |
2020-07-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
US20220125777A1
(en)
|
2019-02-01 |
2022-04-28 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
US20200316064A1
(en)
*
|
2019-02-15 |
2020-10-08 |
Incyte Corporation |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
US11472791B2
(en)
|
2019-03-05 |
2022-10-18 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US20220241412A1
(en)
|
2019-05-24 |
2022-08-04 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
EP3976043A1
(en)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
CN112010844B
(zh)
*
|
2019-05-31 |
2023-07-25 |
中国药科大学 |
N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
TW202114685A
(zh)
*
|
2019-06-20 |
2021-04-16 |
大陸商江蘇恒瑞醫藥股份有限公司 |
藥物組合物以及其製備方法
|
CN110143948B
(zh)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
Cdk4/6抑制剂、其药物组合物、制备方法及应用
|
CA3144791A1
(en)
|
2019-07-07 |
2021-01-14 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
JP2022543062A
(ja)
|
2019-08-01 |
2022-10-07 |
インサイト・コーポレイション |
Ido阻害剤の投与レジメン
|
AR119765A1
(es)
|
2019-08-14 |
2022-01-12 |
Incyte Corp |
Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
|
CN118986983A
(zh)
|
2019-08-26 |
2024-11-22 |
阿尔维纳斯运营股份有限公司 |
用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
EP4041731A1
(en)
|
2019-10-11 |
2022-08-17 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
US11607416B2
(en)
|
2019-10-14 |
2023-03-21 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
CN112759589B
(zh)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
嘧啶并吡啶酮类化合物及其应用
|
WO2021108803A1
(en)
|
2019-11-26 |
2021-06-03 |
Theravance Biopharma R&D Ip, Llc |
Fused pyrimidine pyridinone compounds as jak inhibitors
|
AU2020396093A1
(en)
|
2019-12-03 |
2022-05-19 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
JP2023505257A
(ja)
|
2019-12-04 |
2023-02-08 |
インサイト・コーポレイション |
Fgfr阻害剤の誘導体
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
AU2020405427B2
(en)
|
2019-12-16 |
2025-01-09 |
Lunella Biotech, Inc. |
Selective CDK4/6 inhibitor cancer therapeutics
|
AU2020406362A1
(en)
*
|
2019-12-16 |
2022-07-07 |
Lunella Biotech, Inc. |
Selective CDK4/6 inhibitor cancer therapeutics
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
WO2021176349A1
(en)
|
2020-03-05 |
2021-09-10 |
Pfizer Inc. |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
KR20230017165A
(ko)
|
2020-03-06 |
2023-02-03 |
인사이트 코포레이션 |
Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
|
JP7549032B2
(ja)
*
|
2020-03-13 |
2024-09-10 |
プロセネスター エルエルシー |
CDK阻害剤としてのピリド[2,3-d]ピリミジン-7(8H)-オン
|
US20230118053A1
(en)
*
|
2020-03-27 |
2023-04-20 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
AU2021254794A1
(en)
|
2020-04-16 |
2022-12-15 |
Incyte Corporation |
Fused tricyclic KRAS inhibitors
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
AU2021273744A1
(en)
|
2020-05-19 |
2022-12-08 |
Pharmacosmos Holding A/S |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
EP4157847A4
(en)
*
|
2020-05-28 |
2024-06-19 |
University of Washington |
Drug-like molecules and methods for the therapeutic targeting of viral rna structures
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
CN113880809B
(zh)
|
2020-07-03 |
2022-10-18 |
盛世泰科生物医药技术(苏州)有限公司 |
一种嘧啶类衍生物及其制备方法和应用
|
MX2023000735A
(es)
|
2020-07-15 |
2023-02-13 |
Pfizer |
Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
|
JP2022020583A
(ja)
|
2020-07-20 |
2022-02-01 |
ファイザー・インク |
併用療法
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
WO2022063119A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
南京济群医药科技股份有限公司 |
一种羟乙磺酸哌柏西利的组合物及药物
|
CN114306245A
(zh)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
无定形固体分散体的药物组合物及其制备方法
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
CN112569361B
(zh)
*
|
2020-12-30 |
2023-01-10 |
扬子江药业集团上海海尼药业有限公司 |
一种哌柏西利干混悬组合物及其制备方法
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
TW202313610A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為fgfr抑制劑之三環雜環
|
US20240287065A1
(en)
*
|
2021-06-09 |
2024-08-29 |
Tyk Medicines (Zhengzhou) , Inc. |
Compound as cdk kinase inhibitor and use thereof
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
EP4367117A1
(en)
|
2021-07-07 |
2024-05-15 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
JP2024529347A
(ja)
|
2021-07-14 |
2024-08-06 |
インサイト・コーポレイション |
Krasの阻害剤としての三環式化合物
|
EP4376848A1
(en)
|
2021-07-26 |
2024-06-05 |
Celcuity Inc. |
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
|
CA3229855A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
CN113683612B
(zh)
*
|
2021-09-07 |
2022-06-17 |
山东铂源药业股份有限公司 |
一种帕布昔利布的制备方法
|
WO2023040914A1
(zh)
*
|
2021-09-14 |
2023-03-23 |
甘李药业股份有限公司 |
一种cdk4/6抑制剂的医药用途
|
WO2023049697A1
(en)
|
2021-09-21 |
2023-03-30 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
EP4408536A1
(en)
|
2021-10-01 |
2024-08-07 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
JP2024539651A
(ja)
|
2021-10-14 |
2024-10-29 |
インサイト・コーポレイション |
Krasの阻害剤としてのキノリン化合物
|
KR20240122783A
(ko)
|
2021-11-22 |
2024-08-13 |
인사이트 코포레이션 |
Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
|
US20230203010A1
(en)
|
2021-12-03 |
2023-06-29 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
CA3240454A1
(en)
|
2021-12-10 |
2023-06-15 |
Lacey Morgan LITCHFIELD |
Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibito
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
EP4452982A1
(en)
|
2021-12-22 |
2024-10-30 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
TW202341982A
(zh)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2抑制劑及其用途
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
CR20240408A
(es)
|
2022-03-07 |
2024-11-22 |
Incyte Corp |
Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
|
HU231594B1
(hu)
*
|
2022-05-10 |
2025-03-28 |
Egis Gyógyszergyár Zrt. |
Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
EP4302755B1
(en)
|
2022-07-07 |
2025-08-20 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
CN117430597A
(zh)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
用作cdk4激酶抑制剂的化合物及其应用
|
WO2024023703A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
|
AU2023336057A1
(en)
|
2022-08-31 |
2025-03-27 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
TWI863667B
(zh)
|
2022-11-02 |
2024-11-21 |
美商佩特拉製藥公司 |
用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
TW202440571A
(zh)
*
|
2022-12-16 |
2024-10-16 |
大陸商上海岸闊醫藥科技有限公司 |
化合物及其用途
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
WO2024201340A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
|
WO2024201334A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
|
US20240390340A1
(en)
|
2023-04-18 |
2024-11-28 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
US20240368156A1
(en)
|
2023-04-18 |
2024-11-07 |
Incyte Corporation |
2-azabicyclo[2.2.1]heptane kras inhibitors
|
TW202508598A
(zh)
|
2023-05-05 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
癌症療法
|
WO2024235844A1
(en)
|
2023-05-12 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods of preventing on-target genotoxicity induced by nucleases
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
US20250163079A1
(en)
|
2023-11-01 |
2025-05-22 |
Incyte Corporation |
Kras inhibitors
|
US20250177414A1
(en)
|
2023-12-04 |
2025-06-05 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
WO2025129002A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|
WO2025202854A1
(en)
|
2024-03-27 |
2025-10-02 |
Pfizer Inc. |
Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
|